• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
NKTR

NKTR

Nektar Therapeutics

NASDAQHealthcareBiotechnologyUS

USD59.23

+0.67 (+1.14%)

Rating:C-

Company Profile

CEO

Howard W. Robin

IPO Date

1994-05-03

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$58.51

Prev. Close

$58.56

Day Low

$58.16

Day High

$60.07

52W Low

$7.99

52W High

$109.00

Market Cap

$1.16B

Volume

0.89M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

18.7%

Avg Negative

11.0%

Avg Neutral

70.2%

News Feed

Nektar to Announce Financial Results for the Second Quarter 2021 on Thursday, August 5, 2021, After Close of U.S.-Based Financial Markets

PRNewsWire·7/27/2021·↓ negative

Nektar Appoints Dimitry S.A. Nuyten, M.D.

PRNewsWire·7/19/2021·↓ negative

Nektar In Renal Cell Carcinoma: An Overview

Seeking Alpha·7/10/2021·↑ positive

Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference

PRNewsWire·6/7/2021·↓ negative

Nektar Therapeutics Announces First Publication of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational Autoimmunity

PRNewsWire·5/20/2021·↑ positive

Nektar Therapeutics Announces its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC)

PRNewsWire·5/18/2021·↑ positive

Nektar (NKTR) Moves 8.5% Higher: Will This Strength Last?

Zacks Investment Research·5/10/2021·↑ positive

Nektar Therapeutics (NKTR) CEO Howard Robin on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/7/2021·↓ negative

Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research·5/6/2021·↑ positive

Nektar Therapeutics Reports First Quarter 2021 Financial Results

PRNewsWire·5/6/2021·↓ negative